| Customization: | Available |
|---|---|
| Application: | Internal Medicine |
| Usage Mode: | For external use |
|
Still deciding? Get samples of US$ 0.001/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product name | Lysine Acetylsalicylate For Injection |
| Specificaton | 0.9/1.8g |
| Certification | GMP ISO9001 ISO14001 |
| Standard | BP/CP |
| fuction | Not suitable for oral administration of fever and moderate pain treatment. |
| taboo | 1. Patients with active peptic ulcer or gastrointestinal bleeding caused by other reasons are forbidden; 2. Hemophilia or thrombocytopenia; 3. People with a history of allergy to aspirin or other non-steroidal anti-inflammatory drugs, especially those with asthma, neurovascular edema or shock, should not be used; 4. Pregnant women are prohibited; Disabled for children within 5.3 months. |
| Announcements | Avoid co-administration with other non-steroidal anti-inflammatory drugs, including selective COX-2 inhibitors. 2. According to the need to control symptoms, use the lowest effective dose in the shortest treatment time to minimize adverse reactions. 3. At any time during treatment with all non-steroidal anti-inflammatory drugs, adverse reactions such as gastrointestinal bleeding, ulcers and perforation may occur, and the risk may be fatal. These adverse reactions may or may not be accompanied by warning symptoms, regardless of whether the patient has a history of gastrointestinal adverse reactions or serious gastrointestinal events. Patients with a previous history of gastrointestinal diseases (ulcerative colitis, Crohn's disease) should use non-steroidal anti-inflammatory drugs with caution to avoid worsening the condition. When patients take the drug and develop gastrointestinal bleeding or ulcers, the drug should be discontinued. The frequency of adverse reactions in elderly patients using non-steroidal anti-inflammatory drugs, especially gastrointestinal bleeding and perforation, can be fatal. 4. Clinical trials for a variety of COX-2 selective or non-selective NSAIDs with a duration of up to 3 years show that this product may cause serious cardiovascular thrombotic adverse events, increased risks of myocardial infarction and stroke, and the risk may be deadly. All NSAIDs, including COX-2 selective or non-selective drugs, may have similar risks. Patients with cardiovascular disease or cardiovascular disease risk factors are at greater risk. Even if there are no previous cardiovascular symptoms, doctors and patients should remain vigilant about the occurrence of such events. Patients should be informed of the symptoms and/or signs of severe cardiovascular safety and the steps to be taken if they occur. Patients should be alert to symptoms and signs such as chest pain, shortness of breath, weakness, slurred speech, etc., and should seek medical help immediately after any of the above symptoms or signs occur. 5. Like all non-steroidal anti-inflammatory drugs (NSAIDs), this product can cause new hypertension or aggravate existing hypertension symptoms, any of which can lead to an increased incidence of cardiovascular events. When patients taking thiazides or loop diuretics take non-steroidal anti-inflammatory drugs (NSAIDs), the efficacy of these drugs may be affected. Patients with hypertension should use non-steroidal anti-inflammatory drugs (NSAIDs), including this product, with caution. Blood pressure should be closely monitored at the beginning of treatment with this product and throughout the course of treatment. 6. Patients with a history of hypertension and/or heart failure (such as fluid retention and edema) should be used with caution. 7.NSAIDs, including this product may cause fatal and serious skin adverse reactions, such as exfoliative dermatitis, Stevens Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). These serious incidents can occur without warning. Patients should be informed of the symptoms and signs of severe skin reactions, and this product should be discontinued when skin rashes or other signs of allergic reactions appear for the first time. 8. Those who are weak or have a body temperature of 40 ºC or higher should strictly control the dosage to avoid excessive sweating and collapse. 9. Patients with severe liver damage, hypothrombin prothrombinemia, vitamin K deficiency, and thrombocytopenia should be avoided from using this product, and should be stopped one week before surgery. 10. The following situations should be used with caution: (1) History of asthma and other allergic reactions; (2) Those who lack glucose-6-phosphate dehydrogenase (this product occasionally causes hemolytic anemia); (3) Gout (this product can affect the effect of other uric acid drugs, and may cause uric acid retention in small doses); (4) Hepatotoxicity and bleeding tendency can be aggravated when liver function declines. Patients with liver insufficiency and cirrhosis are prone to adverse renal reactions; (5) Patients with heart failure or high blood pressure may cause heart failure or pulmonary edema when used in large amounts; (6) Renal insufficiency may increase the risk of renal toxicity. 11. It is not effective for various traumatic severe pain and visceral smooth muscle colic. 12. This medicine can cause anaphylactic shock. The doctor should ask the patient about the history of drug allergy and closely monitor the medication. If symptoms and signs such as rash, itching, dyspnea, laryngeal edema, and blood pressure drop occur, the drug should be stopped immediately and treated in time. 13. The drug can cause severe skin damage, including bullous rash, toxic epidermal necrolysis, and exfoliative dermatitis. If the patient has adverse reactions such as skin rash, itching, etc. after taking the medicine, the medicine should be discontinued immediately and seek medical treatment in time. |
){kind=link}